FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Caraco Pharmaceutical Laboratories Oxcarbazepine Tablets Recall

Oxcarbazepine Tablets, 300 mg, 100 tablet bottles, Rx Only

Caraco Pharmaceutical Laboratories Ltd. · Cranbury, NJ

Risk level
Class II
Reported by FDA
Feb 19, 2014
Recall ID
D-1081-2014
Check your lot numberHow we source this data

Summary

Caraco Pharmaceutical Laboratories recalled Oxcarbazepine Tablets starting Jan 29, 2014. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1081-2014 on Feb 19, 2014. Reason: Failed Tablet Specifications: Broken Tablets Present. Status: Terminated.

Why it was recalled

Failed Tablet Specifications: Broken Tablets Present.

Product description

Oxcarbazepine Tablets, 300 mg, 100 tablet bottles, Rx Only. Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijiah McCoy Drive, Detroit, MI, 48202. Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India. NDC 62756-184-88, Rx only, 100 Tablets; Pharmacist: Dispense the Medication Guide provided separately to each patient. Each film-coated tablet contains 300 mg oxcarbazepine, USP, Usual Dosage: See package insert, Dispense in tight container (USP) tore at 25 C (77 F) excursions permitted.... Distributed by Caraco Pharmaceuticals Detroit, MI....

Lot numbers, UPCs & expiration codes

Lot #: JKM7075A, Expiry:10/15

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1081-2014
Classification
Class II
Status
Terminated
Recall initiated
Jan 29, 2014
FDA report date
Feb 19, 2014
Quantity
7005 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Caraco Pharmaceutical Laboratories Ltd.

Original FDA data

Every field from FDA enforcement report D-1081-2014, exactly as published.

Show all FDA fields
City
Cranbury
State
NJ
Status
Terminated
Country
United States
Event ID
67426
Address
270 Prospect Plains Rd
Code information
Lot #: JKM7075A, Expiry:10/15
Postal code
08512-3605
Report date
Feb 19, 2014
Product type
Drugs
Recall number
D-1081-2014
Classification
Class II
Recalling firm
Caraco Pharmaceutical Laboratories Ltd.
Product quantity
7005 bottles
Termination date
Sep 29, 2014
Reason for recall
Failed Tablet Specifications: Broken Tablets Present.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Oxcarbazepine Tablets, 300 mg, 100 tablet bottles, Rx Only. Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijiah McCoy Drive, Detroit, MI, 48202. Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India. NDC 62756-184-88, Rx only, 100 Tablets; Pharmacist: Dispense the Medication Guide provided separately to each patient. Each film-coated tablet contains 300 mg oxcarbazepine, USP, Usual Dosage: See package insert, Dispense in tight container (USP) tore at 25 C (77 F) excursions permitted.... Distributed by Caraco Pharmaceuticals Detroit, MI....
Distribution pattern
Nationwide
Recall initiation date
Jan 29, 2014
Initial firm notification
E-Mail
Center classification date
Feb 10, 2014

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1081-2014, published Feb 19, 2014. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls